Search

Displaying results 8361 - 8370 of 8545 in total
  1. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  2. Drug

    Plozalizumab

    go.drugbank.com/drugs/DB12520
    Investigational

    Plozalizumab has been investigated for the treatment of Atherosclerosis.

  3. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    Linaprazan glurate has a monoisotopic molecular weight of 480.24 Da.

  4. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31.

  5. Drug

    Mirfentanil

    go.drugbank.com/drugs/DB09175
    Experimental

    At high doses, it exhibits analgesic activity which is not fully reversed by opioid antagonists, suggesting that the drug has both opioid and non-opioid mechanisms of action.

  6. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function

  7. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  8. Drug

    5'-Guanosine-Diphosphate-Monothiophosphate

    go.drugbank.com/drugs/DB01864
    Experimental

    A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific

  9. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous

  10. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.